MX2021008113A - Methods for treating or preventing asthma by administering an il-4r antagonist. - Google Patents
Methods for treating or preventing asthma by administering an il-4r antagonist.Info
- Publication number
- MX2021008113A MX2021008113A MX2021008113A MX2021008113A MX2021008113A MX 2021008113 A MX2021008113 A MX 2021008113A MX 2021008113 A MX2021008113 A MX 2021008113A MX 2021008113 A MX2021008113 A MX 2021008113A MX 2021008113 A MX2021008113 A MX 2021008113A
- Authority
- MX
- Mexico
- Prior art keywords
- antagonist
- treating
- methods
- administering
- preventing asthma
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 208000006673 asthma Diseases 0.000 title abstract 2
- 102000010787 Interleukin-4 Receptors Human genes 0.000 abstract 2
- 108010038486 Interleukin-4 Receptors Proteins 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods featured in the invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461943019P | 2014-02-21 | 2014-02-21 | |
EP14306413 | 2014-09-15 | ||
US201462077669P | 2014-11-10 | 2014-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021008113A true MX2021008113A (en) | 2021-10-13 |
Family
ID=51570453
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016010854A MX2016010854A (en) | 2014-02-21 | 2015-02-20 | Methods for treating or preventing asthma by administering an il-4r antagonist. |
MX2021008113A MX2021008113A (en) | 2014-02-21 | 2016-08-19 | Methods for treating or preventing asthma by administering an il-4r antagonist. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016010854A MX2016010854A (en) | 2014-02-21 | 2015-02-20 | Methods for treating or preventing asthma by administering an il-4r antagonist. |
Country Status (13)
Country | Link |
---|---|
US (3) | US10137193B2 (en) |
EP (3) | EP4382164A2 (en) |
JP (2) | JP6673840B2 (en) |
KR (3) | KR102368450B1 (en) |
CN (1) | CN106232140A (en) |
AU (2) | AU2015218808B2 (en) |
CA (1) | CA2940295A1 (en) |
ES (1) | ES2897631T3 (en) |
MX (2) | MX2016010854A (en) |
PL (1) | PL3107575T3 (en) |
PT (2) | PT3973987T (en) |
RU (1) | RU2713406C2 (en) |
WO (1) | WO2015127229A1 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
IN2015KN00414A (en) | 2012-08-21 | 2015-07-17 | Sanofi Sa | |
TWI633891B (en) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor |
RS59354B1 (en) | 2013-06-21 | 2019-10-31 | Sanofi Biotechnology | Methods for treating nasal polyposis by administering an il-4r antagonist |
TWI682781B (en) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
SI3019167T1 (en) | 2013-07-12 | 2021-04-30 | Knopp Biosciences Llc | Treating elevated levels of eosinophils and/or basophils |
PL3107575T3 (en) | 2014-02-21 | 2022-01-17 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
CN106062000B (en) | 2014-02-28 | 2021-05-28 | 瑞泽恩制药公司 | Methods of treating skin infections by administering IL-4R antagonists |
IL294554B2 (en) | 2014-11-14 | 2023-11-01 | Regeneron Pharma | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
US20180056018A1 (en) * | 2016-08-31 | 2018-03-01 | Cephalon, Inc. | Inhalation Systems, Devices and Methods |
EP3506931A1 (en) * | 2016-09-01 | 2019-07-10 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an il-4r antagonist |
TWI784988B (en) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | Methods of treating inflammatory conditions |
CN110431240A (en) * | 2017-04-13 | 2019-11-08 | 雷杰纳荣制药公司 | The treatment and inhibition of the inflammatory lung disease of patient in the gene of coding IL33 and IL1RL1 with risk allele |
EP3645010A4 (en) | 2017-06-27 | 2021-03-24 | Ohio State Innovation Foundation | Liponucleotide-based therapy for asthma |
US11154621B2 (en) | 2017-06-27 | 2021-10-26 | Ohio State Innovation Foundation | Liponucleotide-based therapy for COPD |
WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
MA46269A (en) | 2017-08-18 | 2019-07-31 | Regeneron Pharma | METHODS OF TREATING SEVERE ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R INHIBITOR |
US11034768B2 (en) * | 2017-10-30 | 2021-06-15 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
CN112153982A (en) | 2018-05-13 | 2020-12-29 | 瑞泽恩制药公司 | Method for treating atopic dermatitis by administering an IL-4R inhibitor |
CN110872349A (en) | 2018-09-04 | 2020-03-10 | 三生国健药业(上海)股份有限公司 | Antibodies that bind human IL-4R, methods of making, and uses thereof |
CN111514292B (en) | 2018-12-25 | 2023-06-20 | 江苏荃信生物医药股份有限公司 | Pharmaceutical use of anti-human interleukin 4 receptor alpha monoclonal antibody |
AU2019412405A1 (en) * | 2018-12-27 | 2021-09-02 | Akeso Biopharma, Inc | Antibody against human IL-4RA and use thereof |
BR112021018627A2 (en) | 2019-03-21 | 2021-11-23 | Regeneron Pharma | Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for the treatment of allergy |
SG11202111255YA (en) * | 2019-05-01 | 2021-11-29 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-33 antagonist |
CN115175700A (en) * | 2019-07-16 | 2022-10-11 | 赛诺菲生物技术公司 | Methods for treating or preventing asthma by administering IL-4R antagonists |
KR20220042217A (en) | 2019-08-05 | 2022-04-04 | 리제너론 파아마슈티컬스, 인크. | A method for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist |
CA3161037A1 (en) * | 2019-12-09 | 2021-06-17 | Sanofi Biotechnology | Methods for treating digitally-identified il-4/il-13 related disorders |
EP3992974A1 (en) | 2020-11-02 | 2022-05-04 | Sanofi Biotechnology | Methods for treating digitally-identified il-4/il-13 related disorders |
CN116419746A (en) * | 2020-08-05 | 2023-07-11 | 阿瑞泰治疗公司 | Use of dexpramipexole for the treatment of moderate to severe asthma |
WO2022076289A1 (en) * | 2020-10-05 | 2022-04-14 | Sanofi Biotechnology | Methods for treating asthma in pediatric subjects by administering an il-4r antagonist |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8808015D0 (en) | 1988-04-06 | 1988-05-05 | Ritter M A | Chemical compounds |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
US5714146A (en) | 1992-08-26 | 1998-02-03 | Board Of Regents Of The University Of Washington | IL-4 bone therapy |
EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
MXPA02011682A (en) | 2000-05-26 | 2003-05-14 | Immunex Corp | Use of interleukin-4 antagonists and compositions thereof. |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
CA2543982C (en) | 2003-11-07 | 2013-01-08 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
AU2004309373A1 (en) | 2003-12-22 | 2005-07-14 | Amgen Inc. | Methods for identifying functional antibodies |
WO2005085284A1 (en) | 2004-02-27 | 2005-09-15 | Regeneron Pharmaceuticals, Inc. | Il-4/il-13 sepecific polypetides and therapeutic uses thereof |
US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
TWI306862B (en) | 2005-01-03 | 2009-03-01 | Hoffmann La Roche | Antibodies against il-13 receptor alpha 1 and uses thereof |
KR20080098382A (en) * | 2006-01-24 | 2008-11-07 | 도만티스 리미티드 | Ligands that bind il-4 and/or il-13 |
BRPI0712224B8 (en) | 2006-06-02 | 2021-05-25 | Regeneron Pharma | high affinity antibodies to the human IL-6 receptor and pharmaceutical compositions |
ES2466669T3 (en) | 2006-10-02 | 2014-06-10 | Regeneron Pharmaceuticals, Inc. | Human antibodies with high affinity for the human IL-4 receptor |
US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
EP2022507A1 (en) | 2007-08-07 | 2009-02-11 | Universität Hamburg | Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy |
EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
EP2604628A3 (en) * | 2007-12-21 | 2013-08-21 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4R) - 173 |
WO2010065557A2 (en) | 2008-12-01 | 2010-06-10 | Cincinnati Children's Hospital Medical Center | Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis |
WO2010120511A2 (en) | 2009-03-31 | 2010-10-21 | Altair Therapeutics, Inc. | Method of treating respiratory disorders |
WO2011156000A2 (en) * | 2010-06-07 | 2011-12-15 | Aerovance, Inc. | Use of il-4/il-13 antagonists to treat eosinophilic disorders |
EP3354280B1 (en) | 2010-10-06 | 2020-07-29 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
RU2013122123A (en) * | 2010-10-15 | 2014-11-20 | Медиммьюн Лимитед | THERAPEUTIC MEANS FOR IMPROVEMENT OF PULMONARY FUNCTION |
US20130052190A1 (en) | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
AU2012332859A1 (en) * | 2011-11-01 | 2014-05-22 | Medimmune, Llc | Methods for reducing the frequency and severity of acute exacerbations of asthma |
IN2015KN00414A (en) * | 2012-08-21 | 2015-07-17 | Sanofi Sa | |
EP4374919A2 (en) | 2012-09-07 | 2024-05-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
RS59354B1 (en) | 2013-06-21 | 2019-10-31 | Sanofi Biotechnology | Methods for treating nasal polyposis by administering an il-4r antagonist |
PL3107575T3 (en) * | 2014-02-21 | 2022-01-17 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
IL294554B2 (en) | 2014-11-14 | 2023-11-01 | Regeneron Pharma | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
US11034768B2 (en) * | 2017-10-30 | 2021-06-15 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
-
2015
- 2015-02-20 PL PL15708991T patent/PL3107575T3/en unknown
- 2015-02-20 KR KR1020167025669A patent/KR102368450B1/en active IP Right Grant
- 2015-02-20 PT PT211911201T patent/PT3973987T/en unknown
- 2015-02-20 KR KR1020237041236A patent/KR20230167770A/en active Application Filing
- 2015-02-20 ES ES15708991T patent/ES2897631T3/en active Active
- 2015-02-20 PT PT157089913T patent/PT3107575T/en unknown
- 2015-02-20 MX MX2016010854A patent/MX2016010854A/en unknown
- 2015-02-20 CN CN201580020533.9A patent/CN106232140A/en active Pending
- 2015-02-20 EP EP24150594.0A patent/EP4382164A2/en active Pending
- 2015-02-20 EP EP21191120.1A patent/EP3973987B1/en active Active
- 2015-02-20 CA CA2940295A patent/CA2940295A1/en active Pending
- 2015-02-20 JP JP2016552595A patent/JP6673840B2/en active Active
- 2015-02-20 KR KR1020227006120A patent/KR20220029765A/en active Application Filing
- 2015-02-20 AU AU2015218808A patent/AU2015218808B2/en active Active
- 2015-02-20 WO PCT/US2015/016852 patent/WO2015127229A1/en active Application Filing
- 2015-02-20 EP EP15708991.3A patent/EP3107575B1/en active Active
- 2015-02-20 US US14/627,728 patent/US10137193B2/en active Active
- 2015-02-20 RU RU2016136364A patent/RU2713406C2/en active
-
2016
- 2016-08-19 MX MX2021008113A patent/MX2021008113A/en unknown
-
2018
- 2018-10-11 US US16/157,708 patent/US20190125865A1/en not_active Abandoned
-
2020
- 2020-11-26 AU AU2020277191A patent/AU2020277191B2/en active Active
-
2021
- 2021-03-29 US US17/215,604 patent/US20210322546A1/en active Pending
-
2023
- 2023-08-30 JP JP2023139455A patent/JP2023162343A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2897631T3 (en) | 2022-03-02 |
JP2017507139A (en) | 2017-03-16 |
AU2015218808A1 (en) | 2016-09-22 |
EP3107575B1 (en) | 2021-09-01 |
US10137193B2 (en) | 2018-11-27 |
MX2016010854A (en) | 2017-01-05 |
EP4382164A2 (en) | 2024-06-12 |
WO2015127229A1 (en) | 2015-08-27 |
RU2016136364A (en) | 2018-03-22 |
PT3973987T (en) | 2024-04-01 |
KR102368450B1 (en) | 2022-02-28 |
US20210322546A1 (en) | 2021-10-21 |
RU2713406C2 (en) | 2020-02-05 |
AU2020277191B2 (en) | 2024-05-16 |
KR20160113733A (en) | 2016-09-30 |
US20190125865A1 (en) | 2019-05-02 |
EP3107575A1 (en) | 2016-12-28 |
EP3973987A1 (en) | 2022-03-30 |
JP2023162343A (en) | 2023-11-08 |
CA2940295A1 (en) | 2015-08-27 |
PT3107575T (en) | 2021-11-18 |
EP3973987B1 (en) | 2024-01-10 |
PL3107575T3 (en) | 2022-01-17 |
KR20220029765A (en) | 2022-03-08 |
KR20230167770A (en) | 2023-12-11 |
RU2016136364A3 (en) | 2018-10-11 |
CN106232140A (en) | 2016-12-14 |
AU2020277191A1 (en) | 2020-12-24 |
JP6673840B2 (en) | 2020-03-25 |
US20150246119A1 (en) | 2015-09-03 |
AU2015218808B2 (en) | 2020-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021008113A (en) | Methods for treating or preventing asthma by administering an il-4r antagonist. | |
EP4344706A3 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
AU2018253544A1 (en) | Methods for treating or preventing asthma by administering an IL-4R antagonist | |
AU2014284235B2 (en) | Methods for treating nasal polyposis by administering an IL-4R antagonist | |
MX2023000079A (en) | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist. | |
PH12016501966B1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
MX2023008693A (en) | Modulatory polynucleotides. | |
MX2021002406A (en) | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor. | |
MY187540A (en) | Compounds active towards bromodomains | |
NZ737399A (en) | Ccr2 modulators | |
PH12016501830A1 (en) | Inhibitors of c5a for the treatment of viral pneumonia | |
PT3110848T (en) | Methods for treating skin infection by administering an il-4r antagonist | |
MX2018003893A (en) | Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough. | |
MD20170048A2 (en) | Abiraterone acetate formulation and methods of use | |
MX2017000775A (en) | Meningococcus vaccines. | |
MX2017003216A (en) | Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients. | |
MX2018005825A (en) | Modified immune cells and uses thereof. | |
PH12017500348B1 (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
MX2020009966A (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine. | |
MX2019014090A (en) | Methods for the treatment of chronic pouchitis. | |
MX2016001691A (en) | Bag3 receptor binding molecules for use as a medicament. | |
MX2016009665A (en) | Compositions and methods for treating intracerebral hemorrhage. | |
MX2019009243A (en) | Methods for treating or preventing asthma by administering an il-4r antagonist. | |
IL247290A0 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
IL240241B (en) | Antibodies directed to bacillus anthracis protective antigen |